[1] Egerman MA, Glass DJ. Signaling pathways controlling skeletal muscle mass [J]. Crit Rev Biochem Mol Biol, 2014, 49(10): 59-68.
[2] Sala D, Ivanova S, Plana N, et al. Autophagy-regulating TP53INP2 mediates muscle wasting and is repressed in diabetes [J]. J Clin Invest, 2014, 124(5): 1914-1927.
[3] Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies [J]. Nat Rev Drug Discov, 2015, 14(1): 58-74.
[4] De Larichaudy J, Zufferli A, Serra F, et al. TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism [J]. Skelet Muscle, 2012, 2(1): 2.
[5] Patel R, Williams DJ, Cummins C. Mini review: new molecular mediators of glucocorticoid receptor activity in metabolic tissues [J]. Mol Endocrinol, 2014, 28(7): 999-1011.
[6] Kim RY, Yang HJ, Song YM, et al. Estrogen modulates bone morphogenetic protein-induced sclerostin expression through the Wnt signaling pathway [J]. Tissue Eng, 2015, 21(13-14): 2076-2088.
[7] Pelosi M, De Rossi M, Barberi L, et al. IL-6 impairs myogenic differentiation by downmodulation of p90RSK/eEF2 and mTOR/p70S6K axes, without affecting AKT activity [J]. BioMed Res, 2014, 2014: 206026.
[8] Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF-1-Akt/PKB pathway: insights from genetic models [J]. Skelet Muscle, 2011, 1(4): 14.
[9] Babenko NA, Kharchenko VS. Modulation of insulin sensitivity of hepatocytes by the pharmacological downregulation of phospholipase [J]. Int J Endocrinol, 2015, 2015: 794838.
[10] Wang H, Liu D, Cao P, et al. Atrogin-1 affects muscle protein synthesis and degradation when energy metabolism is impaired by the antidiabetes drug berberine [J]. Diabetes, 2010, 59(8): 1879-1889.
[11] Goldman S, Zhang Y, Jin S. Autophagy and adipogenesis. Implications in obesity and type II diabetes [J]. Autophagy, 2010, 6(1): 179-181.
[12] Ezaki JM, Matsumoto N, Takeda-Ezaki M, et al. Liver autophagy contributes to the maintenance of blood glucose and amino acid levels [J]. Autophagy, 2011, 7(7): 727-736.
[13] O'Neill BT, Lauritzen HP, Hirshman MF, et al. Differential role of insulin/IGF-1 receptor signaling in muscle growth and glucose homeostasis [J]. Cell Rep, 2015, 11(8): 1220-1235.
[14] Schiaffino S, Dyar KA, Ciciliot S, et al. Mechanisms regulating skeletal muscle growth and atrophy [J]. FEBS J, 2013, 280(17): 4294-4314.
[15] Akhmedov D, Berdeaux R. The effects of obesity on skeletal muscle regeneration [J]. Front Physiol, 2013, 4: 371.
[16] Rodriguez A, Becerril S, Méndez-Giménez L, et al. Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in mice [J]. Int J Obes, 2015, 39(3): 397-407.
[17] Arounleut P, Bowser M, Upadhyay S, et al. Absence of functional leptin receptor isoforms in the POUND (Lepr(db/lb)) mouse is associated with muscle atrophy and altered myoblast proliferation and differentiation [J]. PLoS One, 2013, 14: e72330.
[18] MacKenzie MG, Hamilton D, Pepin M, et al. Inhibition of myostatin signaling through Notch activation following acute resistance exercise [J]. PLoS One, 2013, 8: e68743.
[19] Carson JA, Baltgalvis KA. Interleukin 6 as a key regulator of muscle mass during cachexia [J]. Exerc Sport Sci Rev, 2010, 38(4): 168-176.
[20] Sindhu S, Thomas R, Shihab P, et al. Obesity is a positive modulator of IL-6R and IL-6 expression in the subcutaneous adipose tissue: significance for metabolic inflammation [J]. PLoS One, 2015, 10: e0133494.
[21] Jorgensen SB, O'Neill HM, Sylow L, et al. Deletion of skeletal muscle SOCS3 prevents insulin resistancein obesity [J]. Diabetes, 2013, 62(1): 56-64.
[22] Gallo D, Gesmundo I, Trovato L, et al. GH-releasing hormone promotes survival and prevents TNF-α-induced apoptosis and atrophy in C2C12 myotubes [J]. Endocrinology, 2015, 156(9): 3239-3252.
[23] Hall DT, Ma JF, Marco SD, et al. Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia [J]. Aging (Albany NY), 2011, 3(8): 702-715.
[24] Fanzani A, Conraads VM, Penna F, et al. Molecular and cellular mechanisms of skeletal muscle atrophy: an update [J]. J Cachexia Sarcopenia Muscle, 2012, 3(3): 163-179.
[25] Schiaffino S, Dyar KA, Ciciliot S, et al. Mechanisms regulating skeletal muscle growth and atrophy [J]. FEBS J, 2013, 280(17): 4294-4314.
[26] Sabio G, Kennedy NJ, Kyros JC, et al. Role of muscle c-Jun NH2-terminal kinase 1 in obesity-induced insulinresistance [J]. Mol Cell Biol, 2010, 30(1): 106-115.
[27] Sishi B, Loos B, Ellis B, et al. Diet induced obesity alters signaling pathways and induces atrophy and apoptosis in skeletal muscle in a pre-diabetic rat model [J]. Exp Physiol, 2011, 96(2): 179-193.
[28] Hong E, Ko HJ, Cho YR, et al. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle [J]. Diabetes, 2009, 58(11): 2525-2535.
[29] Liu Y, Sweeney G. Adiponectin action in skeletal muscle [J]. Best Pract Res Clin Endocrinol Metab, 2014, 28(1): 33-41.
[30] Iwabu M, Yamauchi T, Okada-Iwabu M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca 2+ and AMPK/SIRT1 [J]. Nature, 2010, 464(4293): 1313-1319.
[31] Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance [J]. Front Endocrinol, 2013, 4: 71.
[32] Duan XY, Xie PL, Ma YL, et al. Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway [J]. Amino Acids, 2011, 41(5): 1223-1231.
[33] Di MS, Cammas A, Lian XJ, et al. The translation inhibitor pateamine A prevents cachexiainduced muscle wastingin mice [J]. Nat Commun, 2012, 3: 896.
[34] Khan IM, Dai Perrard XY, Perrard JL, et al. Attenuated adipose tissue and skeletal muscle inflammation inobese mice with combined CD 4 + and CD 8 + T cell deficiency [J]. Atherosclerosis, 2014, 233(2): 419-428.
[35] Li Y, Xu S, Zhang X, et al. Skeletal intramyocellular lipid metabolism and insulin resistance [J]. Biophys Rep, 2015, 1(2): 90-98.
[36] Amati F, Dube JJ, Alvarez-Carnero E, et al. Skeletal muscle triglycerides, diacylglycerols, and ceramides in insulin resistance: another paradox in endurance-trained athletes? [J]. Diabetes, 2011, 60(10): 2588-2597.
[37] Jadhav KS, Dungan CM, Williamson DL. Metformin limits ceramide-induced senescence in C2C12 myoblasts [J]. Mech Ageing Dev, 2013, 134(11-12): 548-559.
[38] Unoki KH, Yamagishi S, Takeuchi M, et al. Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice [J]. Protein Pept Lett, 2010, 17(9): 1177-1181.
[39] Daffu G, del Pozo CH, O'Shea KM, et al. Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond [J]. Int J Mol Sci, 2013, 14(10): 19891-19910.
[40] Wang Z, Li H, Zhang D, et al. Effect of advanced glycosylation end products on apoptosis in human adipose tissuederived stem cells in vitro [J]. Cell Biosci, 2015, 5: 3.
[41] Frost R, Lang CH. mTOR signaling in skeletal muscle during sepsis and inflammation: where does it all go wrong? [J]. Physiology, 2011, 26(2): 83-96.
[42] Schakman O, Kalista S, Barbe C, et al. Glucocorticoid-induced skeletal muscle atrophy [J]. Int J Biochem Cell Biol, 2013, 45(10): 2163-2172.
[43] Patel R, Williams DJ, Cummins CL. Mini review: new molecular mediators of glucocorticoid receptor activity in metabolic tissues [J]. Mol Endocrinol, 2014, 28(7): 999-1011.
[44] Jeong JY, Jeoung NH, Park K, et al. Transcriptional regulation of pyruvate dehydrogenase kinas [J]. Diabetes Metab J, 2013, 36(5): 328-335.
[45] Lee MJ, Pramyothin P, Karastergiou K, et al. Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity [J]. Biochim Biophys Acta, 2014, 1842(3): 473-481.
[46] Mitsuishi M, Miyashita K, Muraki A, et al. Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control [J]. Diabetes, 2009, 58(3): 710-717.
[47] Yoshida T, Tabony AM, Galvez S, et al. Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia [J]. Int J Biochem Cell Biol, 2013, 45(10): 2322-2332.
[48] Clasen BF, Poulsen MM, Escande C, et al. Growth hormone signaling in muscle and adipose tissue of obese human subjects: associations with measuresof body composition and interaction with resveratrol treatment [J]. J Clin Endocrinol Metab, 2014, 99(112): E2565-E2573.
[49] Enns DL, Tiidus PM. The influence of estrogen on skeletal muscle: sex matters [J]. Sports Med, 2010, 40(1): 41-58.
[50] Cipriani C, Pepe J, Piemonte S, et al. Vitamin D and its relationship with obesity and muscle [J]. Int J Endocrinol, 2014, 2014: 841248.
